ID: ALA2086538

Max Phase: Preclinical

Molecular Formula: C17H24N4O5S

Molecular Weight: 396.47

Molecule Type: Small molecule

Representations

Canonical SMILES:  C=CC(=O)Nc1ccc(S(=O)(=O)N2CCN(C(=O)OC(C)(C)C)CC2)cn1

Standard InChI:  InChI=1S/C17H24N4O5S/c1-5-15(22)19-14-7-6-13(12-18-14)27(24,25)21-10-8-20(9-11-21)16(23)26-17(2,3)4/h5-7,12H,1,8-11H2,2-4H3,(H,18,19,22)

Standard InChI Key:  WBCLFDPQCIHJFJ-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 396.47

Molecular Weight (Monoisotopic): 396.1467

AlogP: 1.45

#Rotatable Bonds: 4

Polar Surface Area: 108.91

Molecular Species: NEUTRAL

HBA: 6

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.01

CX Basic pKa: 0.99

CX LogP: 1.14

CX LogD: 1.14

Aromatic Rings: 1

Heavy Atoms: 27

QED Weighted: 0.77

Np Likeness Score: -1.78

References

1. Prime ME, Andersen OA, Barker JJ, Brooks MA, Cheng RK, Toogood-Johnson I, Courtney SM, Brookfield FA, Yarnold CJ, Marston RW, Johnson PD, Johnsen SF, Palfrey JJ, Vaidya D, Erfan S, Ichihara O, Felicetti B, Palan S, Pedret-Dunn A, Schaertl S, Sternberger I, Ebneth A, Scheel A, Winkler D, Toledo-Sherman L, Beconi M, Macdonald D, Muñoz-Sanjuan I, Dominguez C, Wityak J..  (2012)  Discovery and structure-activity relationship of potent and selective covalent inhibitors of transglutaminase 2 for Huntington's disease.,  55  (3): [PMID:22224594] [10.1021/jm201310y]

Source

Source(1):

• Scientific Literature